Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Active Maintenance Improves PFS in mCRC

June 28th 2014

Two active maintenance regimens following disease stabilization with standard induction therapy demonstrated superior disease-free outcomes compared with no treatment in patients with metastatic colorectal cancer.

Ramucirumab Benefit for US Patients With Gastric Cancer Mirrors Global Results

June 27th 2014

A geographic analysis of clinical trial results supporting the use of ramucirumab in advanced gastric cancer demonstrated that patients in the United States and other Western nations experienced similar survival gains and adverse events as did their counterparts in two other regions of the world.

Regorafenib Offers Effective Option for Asian Patients With mCRC

June 27th 2014

Treatment with regorafenib significantly improved OS and PFS in an Asian population of patients with previously treated mCRC.

MM-398 Improves OS, PFS in Phase III Pancreatic Cancer Study

June 27th 2014

Second-line treatment with MM-398 plus 5-FU and leucovorin extended OS, PFS, and ORR compared with 5-FU and leucovorin alone for patients with metastatic pancreatic cancer.

Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRC

June 27th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.

Dr. Tabernero on Sequencing Angiogenesis Inhibitors in mCRC

June 27th 2014

Josep Tabernero, MD, PhD, head, Medical Oncology Department, Vall d'Hebron University Hospital, director, Vall d'Hebron Institute of Oncology, discusses his opinions on which patients with metastatic colorectal cancer should receive aflibercept following bevacizumab.

Ruxolitinib Combo Improves Outcomes in Metastatic Pancreatic Cancer

June 26th 2014

Adding ruxolitinib to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation compared with capecitabine plus placebo.

Adding Cetuximab to Chemoradiation in Non-operable Esophageal Cancer Does Not Improve Survival

June 26th 2014

Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus

Prognostic Scale Developed for Overall Survival in Locally Advanced Pancreatic Cancer

June 26th 2014

Four independent prognostic factors for improved overall survival in patients with locally advanced pancreatic cancer emerged from an analysis of the LAP 07 phase III trial.

Dr. O'Reilly on Nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX in Pancreatic Cancer

June 25th 2014

Eileen M. O'Reilly, MD, associate director, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses using nab-paclitaxel plus gemcitabine versus FOLFIRINOX as treatment for patients with untreated metastatic pancreatic cancer.

Dr. Tempero Discusses Hereditary Pancreatic Cancer

June 25th 2014

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the two main types of hereditary pancreatic cancer.

Dr. Renschler Discusses Updated Results of the MPACT Study

June 20th 2014

Markus Renschler, MD, vice president, global head, Hematology Oncology Medical Affairs at Celgene, discusses updated results of the MPACT study, which examined nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer.

Nab-Paclitaxel Compares Favorably in Pancreatic Cost-Effectiveness Study

June 17th 2014

A regimen of nab-paclitaxel (Abraxane) and gemcitabine is a cost-effective option for the first-line treatment of patients with metastatic pancreatic cancer because it delivers a survival advantage at a price comparable to the cost of an existing combination therapy

RAS Mutations Ready for Prime Time in mCRC

June 12th 2014

A multitude of studies presented over the course of the past year have emphasized the importance of broader RAS mutational analyses outside of traditional KRAS testing for patients with metastatic colorectal cancer.

Dr. Kennedy on the Utilization of Radioactive Microspheres

June 12th 2014

Andrew Kennedy, MD, physician-in-chief, Radiation Oncology, Sarah Cannon, director, Radiation Oncology Research, Sarah Cannon Research Institute, discusses the utilization of radioactive microspheres.

Ramucirumab Misses Primary Endpoint in Phase III HCC Trial

June 11th 2014

The phase III REACH trial, which examined ramucirumab (Cyramza) for the second-line treatment of patients with hepatocellular carcinoma (HCC), failed to meet its primary endpoint of overall survival (OS), as announced by Eli Lilly and Company, the sponsor of the study and developer of the drug.

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Nab-Paclitaxel Explored as Adjuvant Therapy in Pancreatic Cancer

June 4th 2014

While the combination of gemcitabine and nab-paclitaxel (Abraxane) has demonstrated survival benefits for patients with metastatic pancreatic cancer, oncologists are interested in knowing whether the regimen will transfer well into the adjuvant setting

Dr. Bendell Discusses Two Studies in BRAF-Mutated CRC

June 2nd 2014

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses two studies in BRAF-mutated colorectal cancer.

Survival Comparable With Bevacizumab, Cetuximab in mCRC

June 1st 2014

Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with KRAS wild-type metastatic colorectal cancer